What is GeneDx Holdings's stock issuance proceeds?

GeneDx Holdings (WGS) reported stock issuance proceeds of $476K in Q1 2026.

What is the long-term trend for GeneDx Holdings's stock issuance proceeds?

Over 3 years (2021 to 2025), GeneDx Holdings's stock issuance proceeds has grown at a -82.1% compound annual growth rate (CAGR), from $350M to $2.02M.

What does stock issuance proceeds mean?

Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.

GeneDx Holdings WGS Stock Issuance Proceeds

Stock Issuance Proceeds at other companies

Natera, Inc.NTRA

$3.86M+610%

Bio-Rad LaboratoriesBIO

$3.4M-20.9%

Quest DiagnosticsDGX

$65M+124%

RevvityRVTY

$5.44M+107%

IlluminaILMN

$24M-11.1%

Agilent TechnologiesA

$1M0.0%

Other financials

Income statement

See full

Revenue$102.3M+17.4%

Gross profit$68.2M+16.6%

Operating income-$57.5M-1,163%

Net income-$63.3M-870%

EPS (diluted)-$2.16-839%

Balance sheet

See full

Cash & equivalents$94.9M-5.7%

Total debt$96.7M+82.5%

Total equity$254.1M-1.3%

Total assets$506.3M+13.4%

Cash flow

See full

Operating cash flow-$32.4M-418%

CapEx$6.5M+5.3%

Free cash flow-$38.9M-1,059%

Valuation

See full

Market cap$1.72B-24.3%

Enterprise value$1.73B-22.8%

P/S3.9×-3.0×

Profitability

See full

Gross margin69.6%+4.3pp

Operating margin-14.9%—

Net margin-17.6%—

FCF margin3.8%+2.1pp

Returns & leverage

See full

Return on equity-30.4%—

Debt / equity0.4×+0.2×

Current ratio3.1×-0.2×

Where this comes from

Reported directly by GeneDx Holdings in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfCommonStock.

The official record: GeneDx Holdings’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about GeneDx Holdings's stock issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is GeneDx Holdings's stock issuance proceeds?: GeneDx Holdings (WGS) reported stock issuance proceeds of $476K in Q1 2026.
What is the long-term trend for GeneDx Holdings's stock issuance proceeds?: Over 3 years (2021 to 2025), GeneDx Holdings's stock issuance proceeds has grown at a -82.1% compound annual growth rate (CAGR), from $350M to $2.02M.
What does stock issuance proceeds mean?: Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.